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OBJECTIVE — The purpose of this study was to study the association between a parental
history of type 2 diabetes and the metabolic proﬁle as well as the presence of the metabolic
syndrome and diabetes complications in patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS — This was a cross-sectional study design in
1,860 patients with type 1 diabetes from the Finnish Diabetic Nephropathy (FinnDiane) Study
(620patientswithand1,240age-matchedpatientswithoutaparentalhistoryoftype2diabetes).
Informationonparentalhistorywasreceivedfromthetype1diabeticoffspringbyastandardized
questionnaire.
RESULTS — Patients with type 1 diabetes and a positive parental history of type 2 diabetes
had a higher prevalence of the metabolic syndrome (44 vs. 38%; P  0.013) and a metabolic
proﬁle related to insulin resistance (higher BMI, larger waist circumference, and higher triglyc-
erides, A1C, and insulin dose per kilogram) and also had a later onset of type 1 diabetes (17.2 
9.2vs.16.18.9years;P0.008),whichwasalsoconﬁrmedinthepubliclyavailableDiabetes
Control and Complications Trial data set. In contrast, no association was observed with blood
pressure, diabetes complications, or HLA genotype distribution. Parental history of type 2
diabeteswasindependentlyassociatedwithageatonsetoftype1diabetes(oddsratio1.02[95%
CI 1.01–1.03]), BMI (1.07 [1.02–1.12]), triglycerides (1.18 [1.03–1.35]), and insulin dose per
kilogram (1.63 [1.04–2.54]).
CONCLUSIONS — Parentalhistoryoftype2diabetesisassociatedwithalateronsetoftype
1 diabetes, the metabolic syndrome, and a metabolic proﬁle related to insulin resistance.
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P
atients with type 1 diabetes have an
increased risk of cardiovascular
morbidityandmortality.Thisriskis
to a large extent explained by the high
cardiovascular risk attributed to diabetic
nephropathy, but even patients without
nephropathy have a fourfold increased
risk of cardiovascular disease compared
with individuals without diabetes (1).
The metabolic syndrome, a constellation
ofcardiovascularriskfactors(2),isitselfa
risk factor for cardiovascular disease and
type 2 diabetes in the general population
(3). It is noteworthy that metabolic syn-
drome is also a common ﬁnding in pa-
tients with type 1 diabetes (4), but its role
as a cardiovascular risk factor in patients
with type 1 diabetes is less clear (5).
The rapidly growing worldwide epi-
demic of type 2 diabetes has been ex-
plained by obesity and the sedentary
lifestyle of humans in modernity. Al-
though such environmental factors are
undoubtedly important, familial factors
also seem to play a major role in the
pathogenesis of type 2 diabetes. Conse-
quently, offspring of a parent with diabe-
teshavealifetimeriskoftype2diabetesof
40%, and when both parents have type 2
diabetes, the risk is even higher (6). It is
also of note that even in families with a
patient with type 1 diabetes, there is a
higher proportion of relatives with type 2
diabetes (7). The fact that type 1 and type
2 diabetes cluster in families suggests that
some patients may even have a “double
form” of diabetes. However, so far there
are no diagnostic procedures to ﬁnd out
whether a patient has had “two hits,” but
this may be shown through a metabolic
proﬁle that is related to insulin resistance
andfeaturesofthemetabolicsyndromein
patients with type 1 diabetes.
However, data on the consequences
of a family history of type 2 diabetes on
the offspring with type 1 diabetes are still
scarce.Somesupportofaneffectoftype2
diabetes is provided by the Diabetes Con-
trol and Complications Trial (DCCT), in
which improvement of glycemic control
in the intensive treatment arm led to an
increase in weight gain that was greatest
in those with a positive family history of
type 2 diabetes (8). Consequently, we hy-
pothesized that parental history of type 2
diabetes may be associated with a meta-
bolic proﬁle related to insulin resistance,
the metabolic syndrome, and the pres-
ence of late diabetes complications in pa-
tients with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— Thisstudyispartofthe
ongoing nationwide Finnish Diabetic Ne-
phropathy (FinnDiane) Study, with an
aim of ﬁnding clinical, genetic, and envi-
ronmental risk factors for micro- and ma-
crovascular complications of type 1
diabetes. The present study has a cross-
sectional study design. For this analysis,
allpatientswithanageatonsetofdiabetes
35 years and insulin treatment initiated
within 1 year of diagnosis and complete
information on metabolic syndrome, re-
nal status, and parental medical history
were selected from the FinnDiane data-
base (n  3,184) in March 2006. Patients
with a parental history of type 1 diabetes
(n  89) or an unknown type of parental
diabetes (n  145) were excluded. Of the
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parental history of type 2 diabetes. Those
with a positive parental history of type 2
diabetes,comparedwiththosewithaneg-
ative parental history, were signiﬁcantly
older, and, therefore, of the 2,417 pa-
tients with a negative parental history of
type 2 diabetes we randomly selected
1,240 control subjects of matching age.
The matching for age was ﬁrst done by
dividing those with a positive parental
history of type 2 diabetes into octiles re-
garding age. Those with a negative paren-
tal history of diabetes were then ordered
by a random number from zero to one.
Thereafter the control subjects were cho-
sen in numerical order in a 1:2 ratio from
each age-group.
Thelocalethicscommitteesapproved
thestudy,andthestudywasperformedin
accordance with the Declaration of Hel-
sinki. Written informed consent was ob-
tained from each patient.
Patients with type 1 diabetes
Data on medication, cardiovascular sta-
tus, and diabetes complications of the pa-
tientswithtype1diabeteswereregistered
with a standardized questionnaire, which
was completed by the patient’s attending
physician.Coronaryheartdiseasewasde-
ﬁned as diagnosed myocardial infarction,
coronary revascularization, or pharmaco-
logical treatment with long-acting nitro-
glycerin. Stroke was deﬁned as cerebral
infarction or intracerebral hemorrhage.
Cardiovascular hard end points included
diagnosed myocardial infarction, coro-
nary revascularization, or stroke. Renal
status was deﬁned on the basis of the uri-
naryalbuminexcretionrateinatleasttwo
of three overnight or 24-h urine collec-
tions: normal urinary albumin excretion
(20 g/min or 30 mg/24 h [n 
920]), microalbuminuria (20 and
200g/minor30and300mg/24h
[n  221]), macroalbuminuria (200
g/min or 300 mg/24 h [n  459]), or
end-stage renal disease (undergoing dial-
ysis or having a transplanted kidney [n 
260]). Diabetic nephropathy was deﬁned
as macroalbuminuria or end-stage renal
disease. As a measure of insulin sensitiv-
ity, we used an equation for the estimated
glucosedisposalrate(eGDR)modiﬁedfor
use with A1C instead of HbA1 (4). As an-
other marker of insulin sensitivity, we
used the total daily insulin dose per body
weight.Metabolicsyndromewasassessed
according to both the National Choles-
terolEducationProgram(NCEP)IIIcrite-
ria (9) and the International Diabetes
Federation (IDF) deﬁnition (2). Anthro-
pometric data (weight, height, and waist
and hip circumferences) and blood pres-
sure were collected by a trained nurse.
Assays
Fasting blood samples were drawn and
analyzed for A1C and serum lipids and
lipoproteins. A1C was determined by
standardized assays at each center (nor-
mal range 4.0–6.0%) and serum lipid
and lipoprotein concentrationswere mea-
sured at the research laboratory of Helsinki
University Central Hospital, Division of
Cardiology (Helsinki, Finland) by auto-
mated enzymatic methods using a Cobas
Mira analyzer (Hoffman-LaRoche, Basel,
Switzerland).
HLA genotyping
HLAgenotypingwasperformedforaran-
dom set of 1,136 patients, including 63%
of those with a positive and 60% of those
with a negative parental history of type 2
diabetes. HLA-DR and -DQ alleles were
assessed as described earlier. HLA geno-
types were divided into ﬁve risk catego-
riesbasedonthepresenceofvariousrisks
associated with type 1 diabetes and the
observed genotype frequencies in 622 di-
abetic children and 622 affected family
members based on artiﬁcial control sub-
jects in a Finnish population (10).
Parental information
Parental information was obtained from
the diabetic patients by a standardized
questionnairewithan89%sensitivityand
98% speciﬁcity to detect diabetes (11).
History of diabetes was determined sepa-
rately for each parent, and if the parent
haddiabetes,theageatonsetandmodeof
treatment were registered. For the diag-
nosisofparentaltype2diabetes,anageat
onset 50 years or treatment with oral
hypoglycemic agents or diet was re-
quired. Of those 620 patients with a pos-
itive parental history of type 2 diabetes,
327 (53%) had a mother, 248 (40%) had
a father, and 45 (7%) had both parents
withtype2diabetes.Thosewithbothpar-
entswithdiabeteswereexcludedfromthe
subanalyses regarding maternal and pa-
ternal diabetes.
Replication in the DCCT
Toreplicateourﬁndings,wealsousedthe
publicly available database of the DCCT
(available at http://www.gcrc.umn.edu/
gcrc/downloads/dcct.html). The same
criteriaasthoseforthepresentstudywere
used for inclusion, that is, adult patients
with type 1 diabetes with an age at onset
of diabetes 35 years (n  1,197). In the
DCCT, family history of type 2 diabetes
was deﬁned as a ﬁrst-degree relative with
type 2 diabetes (8), and 119 patients had
a positive family history.
Statistical analysis
The statistical signiﬁcance of differences
in categorical variables between groups
wastestedwitha
2test.Continuousvari-
ables were analyzed with a t test if nor-
mallydistributed(resultsarepresentedas
means  SD) or Mann-Whitney U test if
not normally distributed (presented as
medianwithinterquartilerange).Logistic
regression analyses were used to test
whichvariableswereindependentlyasso-
ciated with a parental history of type 2
diabetes.Resultsarepresentedasoddsra-
tios(ORs)(95%CI).Inthelogisticregres-
sion analyses, we included variables with
P  0.05 in univariate analyses. All anal-
yses were performed using SPSS (version
15.0; SPSS Inc., Chicago, IL). P  0.05
was considered statistically signiﬁcant.
RESULTS— We investigated the role
of a parental history of type 2 diabetes in
1,860 patients with type 1 diabetes. The
mean age of the patients with type 1 dia-
betes was 43.5  10.1 years, and 50%
were men. The characteristics of patients
with and without a parental history of
type 2 diabetes are shown in Table 1. Pa-
tients with a positive parental history of
type 2 diabetes had a later onset of type 1
diabetes (Fig. 1), higher BMI, larger waist
circumference, higher triglycerides, and
higher A1C concentrations, whereas no
difference was observed for blood pres-
sure or prevalence of diabetes complica-
tions.Theuseofstrictercriteriafortype1
diabetes deﬁned as an age at onset 25
years did not change the result of a later
onset of type 1 diabetes in offspring of
parents with type 2 diabetes (13.3  6.3
vs.12.66.2years;P0.043),whereas
in those with an age at onset 15 years
there was no difference in the age at onset
oftype1diabetes(9.03.8vs.8.83.8
years; P  0.411).
The frequency of parental type 2 dia-
betes increased with the number of com-
ponents of the metabolic syndrome (29,
32, 35, 36, and 52% in those with one,
two, three, four, and ﬁve components, re-
spectively; P  0.007). The NCEP score
was associated with parental history of
type 2 diabetes after adjustment for age at
onset of diabetes, A1C, and insulin dose
(OR 2.70 [95% CI 1.51–4.81], 5 vs. 1
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[1.04–1.28], the metabolic score ana-
lyzedasacontinuousvariable).Metabolic
syndrome itself showed a weak associa-
tion with parental history of type 2 diabe-
tes (Table 1) and was not signiﬁcant after
adjustment for age at onset of diabetes,
A1C, and insulin dose (data not shown).
Patients with a positive parental history
of type 2 diabetes had also a higher in-
sulin dose per body weight (P  0.008)
and showed a tendency to be more in-
sulin resistant as deﬁned by a lower
eGDR (P  0.055) (Table 1).
In a multivariate analysis, parental
history of type 2 diabetes was indepen-
dentlyassociatedwithageatonsetoftype
1 diabetes (OR 1.02 [95% CI 1.01–
1.03]), BMI (1.07 [1.02–1.12]), triglycer-
ides (1.18 [1.03–1.35]), and insulin dose
per body weight (1.63 [1.04–2.54]) but
notwithwaistcircumference,A1C,orthe
NCEP metabolic syndrome.
Maternal history of type 2 diabetes
Factorsassociatedwithamaternalhistory
of type 2 diabetes are shown in Table 1.
Those with a positive maternal history of
type2diabeteswereolderthanthosewith
a negative maternal history. In the age-
adjusted logistic regression analysis, a
positive maternal history was indepen-
dentlyassociatedwithalateronsetoftype
1 diabetes (OR 1.02 [1.01–1.03]), higher
BMI (1.07 [1.02–1.13]), higher triglycer-
ides (1.18 [1.01–1.38]), higher A1C con-
centration(1.11[1.01–1.22]),andhigher
insulindoseperbodyweight(1.81[1.02–
3.23]) but not with waist circumference,
cardiovascular hard end points, or the
IDF metabolic syndrome. We excluded
eGDR from the model because A1C and
waist circumference are included in the
formulaforeGDR.IfeGDR,however,was
included and A1C and waist circumfer-
ence were excluded from the model,
eGDR was not independently associated
with a parental history of type 2 diabetes.
Paternal history of type 2 diabetes
In the univariate analysis, only a higher
BMI and a higher insulin dose per body
weightwereassociatedwithapositivepa-
ternal history of type 2 diabetes. Those
with a positive paternal history were,
however,notablyyoungercomparedwith
thosewithanegativepaternalhistory(Ta-
ble 1). In a multivariate age-adjusted
model, an independent association with a
paternal history of type 2 diabetes was
found for both insulin dose per body
weight (OR 1.86 [1.02–3.37]) and BMI
(1.05 [1.01–1.09]).
HLA
In the 1,136 patients with data on HLA
available, our typing method identiﬁed
23 different haplotypes. The most com-
mon haplotypes found, with 1% fre-
quency, are listed in supplemental Table
1 (available in an online appendix at
http://dx.doi.org/10.2337/dc08-0472).
DRB1*0401-DQB1*0302 and (DR7)-
DQA1*0201-DQB1*02 (3.6% vs. 1.9%;
P  0.011) were slightly more common
among those with a positive parental his-
tory of type 2 diabetes (35 vs. 30%; P 
0.015), whereas (DR3)-DQA1*05-
DQB1*02 (20 vs. 24%; P  0.033) was
more common among those with a nega-
tive parental history. These differences
were not signiﬁcant after correction for
the number of comparisons. The 85 dif-
ferent HLA genotypes identiﬁed were
Table 1—Clinical characteristics of patients with type 1 diabetes grouped by parental history of type 2 diabetes
Negative parental
history of type 2
diabetes
Positive parental
history of type 2
diabetes P
Positive maternal
history of type 2
diabetes P
Positive paternal
history of type 2
diabetes P
n 1,240 620 327 248
Male sex 50 49 0.431 49 0.688 49 0.711
Age (years) 43.4  10.0 43.9  10.2 0.344 46.1  10.1 0.001 40.8  9.7 0.001
Age at onset of diabetes
(years) 16.1  8.9 17.2  9.0 0.008 17.8  9.2 0.002 16.5  8.7 0.428
BMI (kg/m
2) 25.0  3.5 25.7  3.8 0.001 25.7  3.7 0.001 25.6  3.8 0.010
Waist circumference (cm) 86.1  11.5 88.0  12.0 0.002 88.2  12.2 0.005 87.6  11.8 0.066
HDL cholesterol (mmol/l) 1.38  0.44 1.37  0.46 0.478 1.37  0.45 0.686 1.36  0.47 0.424
Triglycerides (mmol/l) 1.01 (0.75–1.39) 1.06 (0.80–1.62) 0.001 1.10 (0.81–1.63) 0.001 1.02 (0.76–1.58) 0.160
A1C 8.3  1.3 8.4  1.4 0.028 8.5  1.4 0.004 8.2  1.4 0.727
eGDR (mg   kg
1   min
1) 5.6 (4.1–8.1) 5.3 (3.9–7.9) 0.055 5.1 (3.8–7.5) 0.004 5.9 (4.3–8.0) 0.553
Insulin dose (IU/kg) 0.65  0.21 0.68  0.26 0.008 0.68  0.26 0.071 0.70  0.26 0.005
Systolic blood pressure
(mmHg) 137  19 138  19 0.195 139  19 0.082 136  20 0.771
Diastolic blood pressure
(mmHg) 80  10 80  10 0.570 80  9 0.489 79  10 0.854
Antihypertensive medication 49 49 0.974 52 0.439 45 0.194
Coronary heart disease 7.4 9.9 0.070 12 0.005 5.8 0.376
Cardiovascular end points 12 13 0.442 17 0.013 7.7 0.058
Diabetic nephropathy 38 40 0.297 41 0.346 38 0.981
Microalbuminuria 12 13 0.510 12 0.964 15 0.135
Retinal laser treatment 44 44 0.892 48 0.214 40 0.260
Metabolic syndrome IDF 38 43 0.029 46 0.007 36 0.684
Metabolic syndrome NCEP 38 44 0.013 44 0.030 42 0.215
DataaremeansSD,median(interquartilerange),orpercentagesunlessotherwiseindicated.Pvaluesrepresentcomparisonswithnegativeparentalhistoryoftype
2 diabetes.
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for type 1 diabetes, and the distribution
was similar to that of another Finnish
population of patients with type 1 diabe-
tes(10).Nodifferencesinthedistribution
betweenpatientswithorwithoutaparen-
tal history of type 2 diabetes were found
(supplemental Table 2 available in an on-
line appendix).
Replication in the DCCT
In the DCCT, patients with type 1 diabe-
tes and a positive family history of type 2
diabetes had a later onset of type 1 diabe-
tes compared with those with a negative
family history (23.9  6.5 vs. 22.2  6.8
years;P0.008)(Fig.1).Theassociation
of later onset of type 1 diabetes and posi-
tive family history of type 2 diabetes was
also signiﬁcant after adjustment for BMI,
triglycerides, insulin dose, and A1C (data
not shown).
CONCLUSIONS — In the present
study of patients with type 1 diabetes, a
positiveparentalhistoryoftype2diabetes
was associated with a later onset of type 1
diabetes, the metabolic syndrome, and a
metabolic proﬁle related to insulin resis-
tance. To our knowledge, this is the ﬁrst
study to show that a positive parental his-
tory of type 2 diabetes is associated with
the metabolic syndrome in patients with
type1diabetes.Theassociationwasweak
when the metabolic syndrome was ana-
lyzed as a dichotomous variable but
strong when it was analyzed as a contin-
uousscore.Theﬁndingﬁtswellwithdata
from nondiabetic offspring of patients
withtype2diabeteswhoaremoreinsulin
resistant and show components of the
metabolicsyndrome(12).Inaddition,the
present study showed an independent as-
sociation between a parental history of
type 2 diabetes and a higher BMI, higher
triglyceride concentrations, and a higher
insulin dose in favor of a worse metabolic
proﬁle, suggesting the presence of insulin
resistance. Previous studies assessing the
roleofaparentalhistoryoftype2diabetes
in patients with type 1 diabetes are few,
have had their main focus on diabetes
complications, and have only presented
univariate data regarding metabolic pro-
ﬁles. However, in these studies, a positive
family history of type 2 diabetes was as-
sociated with various disturbances in the
lipid proﬁle (8,13), whereas data regard-
inghypertension,obesity,A1C,andinsu-
lin dose have been conﬂicting (8,13–16).
Notably, in the present large-scale study
wewerealsoabletodetectsubtlechanges
in the metabolic proﬁle, and this may be
the reason that we were able to show a
more comprehensive picture of the meta-
bolic disturbances.
In this study, a positive parental his-
tory of type 2 diabetes was not associated
with the presence of late diabetes compli-
cations.However,apositivematernalhis-
toryoftype2diabeteswasassociatedwith
a higher prevalence of cardiovascular
hard end points and coronary heart dis-
ease,althoughtheassociationwasnotsig-
niﬁcant in the age-adjusted multivariate
analysis. Previous studies have indeed
shown an association with intermediate
markers of cardiovascular disease such as
carotid intima-media thickness (17) as
well as with cardiovascular disease itself
(13). Regarding microvascular complica-
tions, a family history of type 2 diabetes
hasbeenassociatedwithdiabeticretinop-
athy (18) and with diabetic nephropathy
in some (13–15,18) but not all (11) stud-
ies. In the present study we did not ob-
serve any association between a parental
history of type 2 diabetes and microvas-
cular complications despite a long dura-
tion of type 1 diabetes and despite
differences in the metabolic risk proﬁle.
These ﬁndings are somewhat surprising,
and the question of why the unfavorable
metabolic risk proﬁle does not translate
into microvascular complications arises.
One explanation may be that the treat-
ment of patients with diabetes has im-
proved during recent years, with most
guidelines recommending effective cardio-
and renoprotective therapies at an early
stage. This strategy may postpone the de-
velopment of diabetes complications or
even prevent the development of compli-
cations despite high risk and eventually
lead to dilution of the data.
In patients with type 2 diabetes, a
family history of the same trait results in
an earlier onset of diabetes (19), which
has been suggested to reﬂect a stronger
genetic susceptibility. Our results, how-
ever, show a later onset of type 1 diabetes
inthosewithapositiveparentalhistoryof
type 2 diabetes. It could be argued that
this ﬁnding is due to inclusion of patients
with type 2 diabetes in the study popula-
tion. However, this does not seem to be
the answer. First, we have used rather
strictcriteriafortype1diabetes,andeven
after the use of more stringent criteria
such as an age at onset of diabetes of 25
years,therewasstillalateronsetoftype1
diabetes in those with a positive parental
history of type 2 diabetes, although the
difference disappeared in those with an
ageatonsetof15years.Second,thefact
that the HLA genotype distribution did
not differ between the groups and resem-
bled that of a childhood-onset type 1 di-
abetespopulationspeaksinfavorofatrue
“type 1” population. Furthermore, the
ﬁndings are also in line with those of a
small Lebanese study on children, in
Figure 1—Distribution of age at onset of type 1 diabetes in individuals with a positive family
history of type 2 diabetes compared with those with a negative family history in the FinnDiane
Study(17.29.0vs.16.18.9years;P0.008)andintheDCCTcohort(23.96.5vs.22.2
6.8 years; P  0.008).
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was associated with a later onset of type 1
diabetes despite similar HLA genotypes
(20). Third, we were also able to replicate
the ﬁnding in the publicly available
DCCT data set. Interestingly, the acceler-
ator hypothesis suggests that obesity and
insulinresistanceresultinanearlieronset
of diabetes (21). In light of this theory,
one would expect patients with type 1 di-
abetesandapositivefamilyhistoryoftype
2diabetestodevelopdiabetesatanearlier
age compared with those with a negative
family history of type 2 diabetes. This
study does not, however, support such a
view.
In type 2 diabetes there is an excess
maternal transmission of type 2 diabetes,
and there are also different consequences
of paternal and maternal type 2 diabetes
(22). In type 1 diabetes, this issue was
previously addresses in only one small
study. Hadjadj et al. (16) showed an as-
sociation between maternal history of
type2diabetesanddiabeticnephropathy,
as well as with insulin resistance and
lower HDL cholesterol in offspring with
type 1 diabetes, whereas paternal type 2
diabeteswasassociatedwithahigherBMI
and larger waist circumference. In the
present study we aimed to assess whether
there is a different effect of maternal and
paternaltype2diabetesinalargersetting,
and the results indicate a slightly worse
metabolic proﬁle in those with a positive
maternal compared with paternal history
of type 2 diabetes. These results should,
however, be interpreted with caution, be-
cause the patients with a paternal history
of type 2 diabetes were 5 years younger
than those with a maternal history and
age-adjustment in the statistical analyses
could not entirely exclude a potential age
bias. Furthermore, there was not sufﬁ-
cient power for the subanalyses because
of the lower number of patients.
Ourstudydesigndoesnotgiveanan-
swer to what in fact is inherited from the
parent with type 2 diabetes, i.e., genes or
theenvironment,butcertainlybothplaya
role.Oneinterestingpointthatmaydilute
our data is that the type 2 diabetes seen in
the parents of patients with type 1 diabe-
tesmightrepresentadifferentkindofdis-
ease. In accordance, a higher proportion
of GAD antibodies and high-risk HLA ge-
notypes have been observed in patients
withtype2diabetesinmixedtype1and2
families (23). In this study, we unfortu-
nately did not have data on HLA geno-
types or GAD antibodies in the parents.
This study also has some other limita-
tions. The information on parental type 2
diabetes was received from the type 1 di-
abetic patients by a questionnaire and not
ﬁrst hand from the parents themselves.
The questionnaire has, however, been
validatedandhasasufﬁcientsensitivityto
detect diabetes. The age matching, com-
pared with age adjustment, might dilute
the data. However, because the age-
difference was rather large between those
with and without a positive parental his-
tory of type 2 diabetes, matching was
consideredmoreappropriate.Notably,ir-
respective of the method chosen, the re-
sultsaresimilar(datanotshown).Inlight
of earlier studies in nondiabetic subjects,
it would have been more informative to
have a direct measure of insulin sensitiv-
ity (clamp) in patients with type 1 diabe-
tes, but this procedure was not feasible in
this large data set.
In summary, parental history of type
2 diabetes is associated with a later onset
of type 1 diabetes, the metabolic syn-
drome, and a metabolic proﬁle related to
insulin resistance.
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